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ABSTRACT 
Aim: The aim of the study was to determine in vitro synergy and postantibiotic effect of 
colistin alone and combined with meropenem or vancomycin against Enterobacteriaceae 
producing multiple carbapenemases; combinations of two metallo-β-lactamases (MBL) or 
MBL with OXA-48.  Colistin-resistant strain positive for OXA-48 was also included in the 
study. 
Methods:  The antibiotic susceptibility was tested by broth microdilution method. Synergy 
was tested by chequerboard, time-kill and 2-well method.  PAE was determined by viable 
counting. 
Results:The chequerboard analysis revealed synergy for colistin combination with meropenem 
in all isolates with FICI values ranging from 0.12 to 0.24. FICI values for combinations with 
vancomycin were below 0.5 indicating synergy in two out of four isolates. K. pneumoniae 
609815 positive for OXA-48 and colistin resistant showed the most pronounced and 
consistent synergy effect with meropenem in both chequerboard and time-kill method. 
Synergy effect in time-kill curves, was observed for  K pneumoniae 145846  with two MBLs 
and  colistin resistant K. pneumoniae 609815 positive for OXA-48, with both combinations 
including meropenem and vancomycin. Colistin alone exhibited short postantibiotic effect 
(PAE) against all tested isolates. Meropenem markedly  prolonged the PAE in two isolates in 
contrast to vancomycin which did not demonstrate significant effect on the duration of PAE 
Conclusions: The synergy effect and the  duration of  PAE was strain and antibiotic dependent 
but not related to the resistance gene content. 
Key words:  carbapenem resistance, Klebsiella pneumoniae, colistin, VIM-1, NDM,-1 OXA-
48 
Carbapenem-resistance in Enterobacteriaceae has increased globally during the past decade, 
particularly in Klebsiella pneumoniae, and is typically associated with carbapenemase 
 
 
production as the most important resistance mechanism [1]. Therapeutic options for infections 
caused by carbapenem-resistant Enterobacteriaceae are limited and colistin is often the only 
remaining treatment option. Colistin (also known as polymyxin E) is a multi-component 
polypeptide antibiotic discovered in the 1950s. However, colistin resistance emerged recently 
in Enterobacteriaceae [2].  Persistent suppression of bacterial growth after short antimicrobial 
exposure is called the postantibiotic effect (PAE) [3].  Both carbapenems and colistin were 
found to produce PAE in Gram-negative bacteria as individual drugs but there are only few 
reports on PAE induced by combination of colistin with carbapenems [4-6]. Clinical studies 
demonstrated that combination antibiotic therapy is associated with better outcome than 
monotherapy for the treatment of severe infections with these strains, even if the isolated 
strains are resistant in vitro to the individual drugs [7]. Improved clinical outcomes have been 
reported for the combinations of colistin and a carbapenem, tigecycline, fosfomycin and 
vancomycin [7]. Recently, isolates with multiple carbapenemases, including combinations of 
VIM-1, NDM-1 and OXA-48, or KPC with  broad spectrum β-lactamase were found in 
Enterobacteriaceae in Zagreb [8-9]. Moreover, colistin resistance was reported in a OXA-48  
producing Klebsiella pneumoniae from Zagreb (unpublished results) and Enterobacter 
aerogenes from Pula [10].  Such isolates pose a serious therapeutic problem in our hospitals, 
particularly in Enterobacter spp which is prone to develop adaptive resistance to colistin due 
to upregulation of efflux pumps or loss of outer membrane porins. There are many reports on 
colistin synergy with other antibiotics against KPC and MBL positive Enterobactericae 
[11.12,13]. However, there are no reports on the synergy testing and PAE induced by colistin 
combination with other antibiotics, in the isolates with multiple carbapenemases, or those 
positive for OXA-48 and colistin resistant. 
 
 
The aim of the study was to determine in vitro synergy and postantibiotic effect of colistin 
alone and combined with meropenem or vancomycin against Enterobacteriaceae producing 
multiple carbapenemases or carbapenemase combined with colistin resistance. 
The study was performed on the collection of  previously characterized strains from Croatia 
[8-9]. The study collection included: Enterobacter cloacae  209377 positive for VIM-1, NDM-
1, OXA-48, TEM-1 and CTX-M-15, Klebsiella pneumoniae 145846 positive for  NDM-1 
VIM-1, TEM-1, and  SHV-11, Klebsiella pneumoniae 38985 positive KPC-2, TEM-1 and 
SHV-11, and Klebsiella pneumoniae  609815  positive for OXA-48, SHV-11 and colistin 
Minimum inhibitory concentrations (MICs) of colistin, vancomycin and meropenem were 
determined by the broth microdilution method according to the CLSI guidelines [14]. 
The synergy of colistin with meropenem or vancomycin was tested by chequerboard method 
yielding the fractional inhibitory concentration index (FICI), 2-well method and  time-kill 
method (TK) as described previously [15 ]. Antibiotic concentrations used during TK 
experiments represented mean steady-state concentrations of non-protein bound drug in 
human body fluids:  4 mg/L for colistin, 10 mg/L for meropenem and 9 mg/L for vancomycin. 
Synergy in TK was defined as ≥ 2 log10 decrease in colony count at 24 h with the 
antimicrobial combination compared to the most active single agent.  Bactericidal effect was 
defined as ≥ 3 log10 decrease in the colony count after 24 h compared with the starting 
inoculum.  PAE was determined by a standard viable counting method after exposure to 
colistin alone and combined with vancomycin or meropenem in the same concentrations as 
for TK. 
All but one strain (609815, OXA-48) were susceptible to colistin with MIC values ranging 
from 0.5 to 2 mg/L. The strains exhibited variable MICs of meropenem with values  ranging 
from 8  to >128 mg/L. The chequerboard analysis revealed synergy for colistin combination 
with meropenem in all tested isolates, with FICI values ranging from 0.12 to 0.24. FICI values 
 
 
for combinations with vancomycin were 0.5 indicating synergy in two isolates (K. 
pneumoniae 14846 and K. pneumoniae 609815- colistin resistant)  and  above 0.5 indicating no 
synergy in the remaining two isolates (Table 1).  2- method revealed the growth of all strains 
at 0.25 x MIC of colistin alone,  but absence of growth when the strains were exposed to 2 x 
MIC of colistin alone (Table 1).  No growth was observed when the strains were exposed to 
0.25 x MIC and 2 x MIC of colistin combined with both meropenem and vancomycin 
confirming synergy in  all tested strains (Table 1). 
Colistin, alone and in any combination with other antibiotics was associated with 3 log 
decrease in CFU/ml during the first hour of the experiments in two (K. pneumoniae 145 846 
positive for NDM-1 and VIM-1 and E. cloacae 209377 positive for VIM-1, NDM-1 and 
OXA-48 ) out of four strains (Fig. 1). However, considerable regrowth occurred for colistin 
alone and in combination,  but the addition of meropenem or vancomycin postponed the 
regrowth for 1 to 3 h, as shown in Fig. 1.  Nevertheless, regrowth occurred in most cases after 
24h, in spite of the additional antibiotic. Bactericidal effects after 24 h were found for the 
combinations with both vancomycin and meropenem, against K. pneumoniae strain 145846 
positive for NDM-1 and VIM-1 positive for two MBLs and E. cloacae 209377  positive for 
VIM-1, NDM-1 and OXA-48   positive for two MBLs and  OXA-48, with CFU reduction of 
3 to 4 log10 compared to the starting inoculum. Synergy effect defined as  ≥ 2 log10 decrease 
with the antibiotic combination compared to colistin alone, was observed for  K pneumoniae 
145846 and colistin resistant K. pneumoniae 609815 positive for OXA-48, with both 
combinations including meropenem (3-4 log10 decrease compared to colistin alone) and  
vancomycin   (2-4 log10 decrease compared to colistin alone) as shown in Table 1 and Fig 1.  
All tested strains exhibited very short to moderate PAEs induced by colistin alone ranging 
from 0.9 h (K. pneumoniae 60815) to 2.6 (E. cloacae 209377) as shown in Table 2 and Fig. 1. 
The duration of PAE was only slightly prolonged by vancomycin in four tested strains and 
 
 
ranged from 1.16 (K. pneumoniae 38985) to 2.8 h (E. cloacae 209377).  Addition of 
meropenem prolonged significantly the duration of PAE (>2h)  in two tested strains (E. 
cloacae 209377 and K. pneumoniae 38985) as shown in Table 2 and Fig. 1. The PAE was 
consistently the longest with E. cloacae 209377  harbouring VIM-,  NDM-1, and OXA-48 
(Table 2).  The addition of meropenem to colistin resulted in synergistic activity in 
chequerboard method  and 2-well method with all tested strains.  This is probably due to 
increased permeability leading to higher concentrations of meropenem in periplasmic space 
with the combination.  However, the synergy in TK was reported only for  K.  pneumoniae 
145846  and for  colistin resistant  K.  pneumoniae  609815. The addition of vancomycin 
produced synergy in TK method with the K. pneumoniae 145846 with two MBLs and colistin 
resistant K.  pneumoniae  609815 which was confirmed by chequerboard method.  2- well 
method found synergy with all tested strains and antibiotic combinations. The discrepancy 
between 2-well and TK can be explained by the fact that 2-well method detects bacteriostatic 
activity while TK method determined bactericidal activity. The discrepancies between 
chequerboard and 2-well method can be explained by the fact that 2-well detects the growth 
or absence of growth with only two different antibiotic concentrations (0.25 x MIC and 2 x 
MIC) whereas chequerboard tests the range of 12 antibiotic dilutions. The differences could 
also be due to the specific characteristics of the strains which are not influenced by the 
resistance gene content.  Moreover, colistin and meropenem, in combination, in 
physiologically attainable concentrations, showed an evident and potent in vitro PAE activity 
in half of the tested strains.. Vancomycin did not significantly prolong the duration of PAE 
induced by colistin. The longest PAE was noticed for  E. cloacae 209377  positive for two 
MBLs, OXA-48 and ESBL. The E. cloacae strain possessed  three carbapenemases and it is 
possible that the acquisition of the resistance genes was on expense of reduced fitness and 
prolonged response to antibiotic exposure.  The shortest PAE was detected for colistin 
 
 
resistant K. pneumoniae which could be explained by ineffectiveness, of colistin, probably 
due to modification of the outer membrane lipopolysaccharide, although the mechanism of the 
colistin resistance was not clarified in this study. Our study demonstrated that the PAE was 
strain and antibiotic dependent, but was not influenced by the type of carbapenemase. 
Biological differences between the strains might have influenced the response to the 
antibiotics and the duration of PAE. The bibliographical data point out to the fact that 
bacterial isolates belonging to the same or different species demonstrate huge differences in 
the duration of PAE  [3-5]. Interestingly, the colistin resistant and OXA-48 positive strain 
showed the most pronounced synergy effect regardless of the testing method, but the addition 
of meropenem or vancomycin did not prolong significantly the duration of PAE.  The possible 
explanation for the synergy effect is that colistin which causes an electrostatic interaction with 
lipid A which consequently discrupts the outer membrane of Gram-negative bacteria allows 
the large molecules such as vancomycin to pass through the lipid layer and reach the receptor 
at the cell wall and enables meropenem to achieve higher concentrations in the periplasmic 
space. Prevention of heteroresistance to colistin could also be one  explanation for the 
synergy, but the population analysis was not done in this study.  Unexpectedly, the 
phenomenon is more pronounced in colistin resistant compared to colistin susceptible strains.  
The KPC-positive organism (38985) exhibited no synergy in TK method neither with 
vancomyin nor with meropenem. This could be explained by increased fitness of this 
individual strain in the presence of antibiotics in comparison with other strains. Moreover, 
KPC carbapenemase exerts very high hydrolysis of carbapenem substrates which could, in 
part, explain the lack of synergy with meropenem. 
The limitation of the study is relatively small number of tested strains and the fact that results 
were strain dependent and method dependent. Our preliminary results on small number of 
tested strains demonstrated that meropenem has a potential of exerting synergy with colistin 
 
 
and prolonging PAE but further study including larger number of isolates are needed to 
confirm these results. 
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FIGURE LEGEND 
Fig. 1. Time kill curves and postantibiotic effect of colistin alone and combined with 
meropenem or vancomycine against strains: K.  pneumoniae  609815  positive for OXA-48, 
SHV-11 and colistin resistant, E. cloacae  209377 positive for VIM-1, NDM-1, OXA-48, 
TEM-1 and CTX-M-15, K.  pneumoniae 145846 positive for  NDM-1 VIM-1, TEM-1, and  
SHV-11 and K.  pneumoniae 38985 positive KPC-2, TEM-1 and SHV-11- Mean value of 
three experiments is shown. 
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Table 1.  Synergistic effect of colistin combined with either vancomycin or meropenem with three different methods 
Strain Chequerboard 
Colistin+ 
vancomycin 
(FICI) 
Chequerboard 
Colistin + 
meropenem 
(FICI) 
Time-kill 
(colistin 
+vancomycin) 
≥2log10 reduction  
Time-kill 
(colistin 
+meropenem) 
≥2log10 reduction  
Two well method 
Colistin+meropenem 
Two well method 
Colistin 
+vancomycin 
Enterobacter 
cloacae  209377 
- (1,003) +  (0.12) -  - Synergy Synergy 
Klebsiella 
pneumoniae -
145846 
+ (0.5) + (0.12) + + Synergy Synergy 
Klebsiella 
pneumoniae 
38985 
- (1,003) + (0.24) - - Synergy Synergy 
Klebsiella 
pneumoniae  
609815 
+ (0.5) + (0.12) + + Synergy Synergy 
 
  
 
Table 2  Duration of postantibiotic effect of colistin alone and combined with vancomycin 
or meropenem (mean value and standard deviation are shown) 
 
Colistin alone 
 
E.cloacae 
209377 
K.pneumoniae 
145846 
K.pneumoniae 
38985 
K.pneumoniae 
609815 
Mean: 2.6 
SD: 0.86 
Mean: 1.26 
SD: 1.15 
Mean: 1.06 
SD: 0.41 
Mean: 0.9 
SD: 0.26 
Colistin + vancomycin 
 
E.cloacae 
209377 
K.pneumoniae 
145846 
K.pneumoniae 
38985 
K.pneumoniae 
609815 
Mean: 2.8 
SD: 0.65 
Mean: 1.38 
SD: 0.68 
Mean: 1.16 
SD: 0.35 
Mean: 1.34 
SD: 0.23 
Colistin+meropenem 
 
E.cloacae 
209377 
K.pneumoniae 
145846 
K.pneumoniae 
38985 
K.pneumoniae 
609815 
Mean: 6.1 
SD: 1.87 
Mean: 1.43 
SD: 0.65 
Mean: 3.16 
SD: 1.75 
Mean: 1.36 
SD: 0.55 
 
